- Home
- ELLO vs CADL Comparison
ELLO vs CADL Comparison
Compare ELLO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$6.35
Company Overview
Basic Information| Metric | ELLO | CADL |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.9M | 339.8M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELLO | CADL |
|---|---|---|
| Price | $21.85 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 3.7K | ★ 936.0K |
| Earning Date | 12-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,322,959.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.00 | $4.25 |
| 52 Week High | $23.95 | $13.68 |
Technical Indicators
Market Signals| Indicator | ELLO | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 72.12 |
| Support Level | $21.82 | $5.39 |
| Resistance Level | $23.95 | $6.83 |
| Average True Range (ATR) | 0.81 | 0.36 |
| MACD | 0.12 | 0.22 |
| Stochastic Oscillator | 60.32 | 80.81 |
Price Performance
Historical Comparison ELLO
CADL
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.